Quality of life and symptoms in postmenopausal women with hormone receptor positive disseminated breast cancer while receiving Faslodex [fulvestrant].
Phase of Trial: Phase IV
Latest Information Update: 01 May 2009
At a glance
- Drugs Fulvestrant (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 01 May 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 01 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Apr 2008 New trial record.